Vanguard Global Advisers
FULC icon

Vanguard Global Advisers’s Fulcrum Therapeutics FULC Stock Holding History

Vanguard Global Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Sell
18,858
-19,661
-51% -$120K ﹤0.01% 2953
2026
Q1 		$295K Buy
+38,519
New +$357K ﹤0.01% 2250

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's FULC Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Fulcrum Therapeutics (FULC) stake by 51% in Q2 2026, selling an estimated $120K and leaving 18,858 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #2953.

Vanguard Global Advisers first reported a position in FULC in Q1 2026 and has held it in 2 quarters since. The position peaked at $295K in Q1 2026. 153 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Vanguard Global Advisers held 18,858 shares of Fulcrum Therapeutics worth $69K as of Q2 2026.
  • Vanguard Global Advisers sold 19,661 Fulcrum Therapeutics shares in Q2 2026, an estimated $120K.
  • Fulcrum Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2953 holding.
  • Vanguard Global Advisers first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Fulcrum Therapeutics position peaked at $295K in Q1 2026.
  • 153 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.